Host determinants of immune-related adverse events during immune checkpoint inhibition
- 1Department of Clinical Laboratory Sciences, Umm Al-Qura University
Abstract
Immune checkpoint inhibitors (ICIs) have transformed the treatment of many cancers, but immune-related adverse events (irAEs) have become their principal limitation. This review argues that irAEs are not a random hazard of checkpoint blockade but a largely host-determined outcome layered on a drug-set baseline. The regimen fixes how much toxicity risk exists and, through the checkpoint it blocks, which organs are most likely affected. Within that envelope, host determinants decide which patient crosses the threshold of tolerance, and where. We synthesise the evidence for four classes of host determinant: germline genetic variation, including the IL7 locus and organ-directing human leucocyte antigen (HLA) alleles; the baseline immune landscape; the gut microbiome and metabolic state; and clinical characteristics led by pre-existing autoimmune disease. We draw two distinctions the literature often blurs. First, susceptibility should be read in two stages: determinants measurable before the first dose, which can triage patients, and on-treatment changes, which can only signal an event already emerging. Second, organ-specific toxicity is neither drug- nor host-intrinsic but the product of their intersection, with HLA restriction and shared tumour-tissue antigens offering the clearest mechanistic account of why a particular organ is struck. One theme runs throughout: many host features that raise irAE risk also predict a better antitumour response, so host stratification is a matter of optimising a benefit-to-toxicity balance rather than screening susceptible patients out. Multi-omics and systems immunology are assembling the measurements needed to act on this biology, but no host-based pre-treatment predictor is yet validated for clinical use. Realising one would shift checkpoint immunotherapy from the reactive management of toxicity toward its anticipation.
Related
- 971 The impact of liver metastases on immune-related adverse events in stage IV patients treated with immune-checkpoint inhibitors: a real-world, multicenter, retrospective study
- Risk of de novo immune-related adverse events in patients with cancer and autoimmune disease receiving immune checkpoint inhibitors
- Baseline circulating immunophenotype as a predictor of immune-related adverse events in NSCLC patients treated with immune checkpoint inhibitors
- Immune Responses in Checkpoint Inhibitor–Associated Cardiovascular Immune–Related Adverse Events
- Immune-related adverse reactions across multiple systems in a non-small cell lung cancer patient induced by immune checkpoint inhibitors: a case report and literature review
BibTeX
@article{alwithenani2026host,
title = {{Host determinants of immune-related adverse events during immune checkpoint inhibition}},
author = {Akram Alwithenani},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1941544},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1941544/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Host determinants of immune-related adverse events during immune checkpoint inhibition
AU - Akram Alwithenani
PY - 2026
DA - 2026/10/14
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1941544
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1941544/full
AB - Immune checkpoint inhibitors (ICIs) have transformed the treatment of many cancers, but immune-related adverse events (irAEs) have become their principal limitation. This review argues that irAEs are not a random hazard of checkpoint blockade but a largely host-determined outcome layered on a drug-set baseline. The regimen fixes how much toxicity risk exists and, through the checkpoint it blocks, which organs are most likely affected. Within that envelope, host determinants decide which patient crosses the threshold of tolerance, and where. We synthesise the evidence for four classes of host determinant: germline genetic variation, including the IL7 locus and organ-directing human leucocyte antigen (HLA) alleles; the baseline immune landscape; the gut microbiome and metabolic state; and clinical characteristics led by pre-existing autoimmune disease. We draw two distinctions the literature often blurs. First, susceptibility should be read in two stages: determinants measurable before the first dose, which can triage patients, and on-treatment changes, which can only signal an event already emerging. Second, organ-specific toxicity is neither drug- nor host-intrinsic but the product of their intersection, with HLA restriction and shared tumour-tissue antigens offering the clearest mechanistic account of why a particular organ is struck. One theme runs throughout: many host features that raise irAE risk also predict a better antitumour response, so host stratification is a matter of optimising a benefit-to-toxicity balance rather than screening susceptible patients out. Multi-omics and systems immunology are assembling the measurements needed to act on this biology, but no host-based pre-treatment predictor is yet validated for clinical use. Realising one would shift checkpoint immunotherapy from the reactive management of toxicity toward its anticipation.
SN - 1663-9812
ER -